Revenue: CHF0.1 million in Q3 2024, compared to CHF0.3 million in Q3 2023.R&D Expenses: CHF0.2 million in Q3 2024, decreased by CHF0.3 million from Q3 2023.G&A
Texas-based Genprex, Inc. (GNPX), a clinical-stage gene therapy company is up over 103 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.
Shares of iRhythm Technologies, Inc. IRTC rose sharply in today's pre-market trading after the company announced that it was granted FDA clearance for its 510(k...
Addex Therapeutics (ADXN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Series A Financing: USD 63 million led by Perceptive Advisors.Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest.Milestone Payments: Up to
California-based Bolt Projects Holdings, Inc. (BSLK) is up over 103 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.
U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.2% on Tuesday.
The Dow traded up 0.01% to 41,242.33 while the NASDAQ rose...
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.
The Dow traded down 0.16% to 41,175.13 while t...
U.S. stocks traded mixed this morning, with the Dow Jones index gaining over 50 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.16...
Ireland-based Trinity Biotech plc (TRIB) is up over 103 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.
Shares of Trip.com Group Limited TCOM rose sharply in today's pre-market trading after reporting second-quarter results.
Trip.com Group posted adjusted earning...